Trials / Completed
CompletedNCT00050843
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | thalidomide |
Timeline
- Start date
- 2001-08-01
- Completion
- 2004-02-01
- First posted
- 2002-12-24
- Last updated
- 2005-06-24
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00050843. Inclusion in this directory is not an endorsement.